• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Akten (lidocaine hydrochloride)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Akten (lidocaine hydrochloride)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Akten is a gel formulation of the local anesthetic agent lidocaine. Akten stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Anesthesia generally occurs between 20 seconds to 1 minute and persists for 5 to 30 minutes.

    Akten is specifically indicated as a local anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures.

    Akten is supplied as an ophthalmic gel (3.5%) containing 35 mg per mL of lidocaine hydrochloride designed for topical ophthalmic administration. The recommended initial dose of the drug is two drops applied to the ocular surface in the area of the planned procedure. Akten may be reapplied to maintain anesthetic effect.

    Clinical Results

    FDA Approval
    FDA approval of Akten was based the results of a multi-center, randomized, controlled, double-blind study. This study enrolled 209 subjects who received placebo or Akten 1.5%, 2.5% or 3.5%. Ocular anesthesia was achieved within five minutes of anesthetic application by 47 of 51 subjects (92%) in the Akten 3.5% group. The mean time to anesthesia onset ranged from 20 seconds to 5 minutes and was not affected by Akten dose. The mean time to anesthesia onset was approximately 60 seconds, with a median onset time of 40 seconds for the Akten 3.5% group. Among the subjects in the Akten groups who achieved anesthesia within 5 minutes, approximately 90% had achieved anesthesia within 60 seconds of application. The duration of anesthesia generally ranged from approximately 5 minutes to 30 minutes, with mean anesthesia durations of approximately 15 minutes for the Akten 3.5% group. Approximately 84% of the subjects in the Akten 3.5% group experienced anesthesia for at least 5 minutes, approximately 55% of subjects experienced anesthesia for 10 minutes or longer and 27% experienced anesthesia for 15 minutes or longer.

    Side Effects

    Adverse events associated with the use of Akten may include, but are not limited to, the following:

    • Conjunctival hyperemia
    • Corneal epithelial changes
    • Headache
    • Burning upon instillation

    Mechanism of Action

    Akten is a gel formulation of the local anesthetic agent lidocaine. Akten stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Anesthesia generally occurs between 20 seconds to 1 minute and persists for 5 to 30 minutes.

    Literature References

    Busbee BG, Alam A, Reichel E Lidocaine hydrochloride gel for ocular anesthesia: results of a prospective, randomized study. Ophthalmic Surgery, Lasers & Imaging : the official journal of the International Society for Imaging in the Eye 2008 Sep-Oct;39(5):386-90

    Amiel H, Koch PS Tetracaine hydrochloride 0.5% versus lidocaine 2% jelly as a topical anesthetic agent in cataract surgery: comparative clinical trial. Journal of Cataract and Refractive Surgery 2007 Jan;33(1):98-100

    Bardocci A, Lofoco G, Perdicaro S, Ciucci F, Manna L Lidocaine 2% gel versus lidocaine 4% unpreserved drops for topical anesthesia in cataract surgery: a randomized controlled trial. Ophthalmology 2003 Jan;110(1):144-9

    Barequet IS, Soriano ES, Green WR, O'Brien TP Provision of anesthesia with single application of lidocaine 2% gel. Journal of Cataract and Refractive Surgery 1999 May;25(5):626-31

    Additional Information

    For additional information regarding Akten or ophthalmologic anesthesia, please visit the Akten web page.
    Approval Date: 2008-10-01
    Company Name: Akorn
    Back to Listings

    Upcoming Events

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing